CN106727872A - The beneficial liver effect of poinsettia and application technology - Google Patents
The beneficial liver effect of poinsettia and application technology Download PDFInfo
- Publication number
- CN106727872A CN106727872A CN201710051786.3A CN201710051786A CN106727872A CN 106727872 A CN106727872 A CN 106727872A CN 201710051786 A CN201710051786 A CN 201710051786A CN 106727872 A CN106727872 A CN 106727872A
- Authority
- CN
- China
- Prior art keywords
- poinsettia
- extract
- medicine
- hepatitis
- contain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000221079 Euphorbia <genus> Species 0.000 title claims abstract description 61
- 230000000694 effects Effects 0.000 title claims abstract description 12
- 210000004185 liver Anatomy 0.000 title claims abstract description 10
- 230000009286 beneficial effect Effects 0.000 title claims abstract description 7
- 238000005516 engineering process Methods 0.000 title abstract description 5
- 238000000605 extraction Methods 0.000 claims abstract 3
- 239000000284 extract Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 208000006454 hepatitis Diseases 0.000 claims description 18
- 231100000283 hepatitis Toxicity 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000000419 plant extract Substances 0.000 claims 1
- 230000000630 rising effect Effects 0.000 claims 1
- 238000012545 processing Methods 0.000 abstract description 2
- 229940126534 drug product Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000005374 Poisoning Diseases 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 231100000572 poisoning Toxicity 0.000 description 3
- 230000000607 poisoning effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 240000002395 Euphorbia pulcherrima Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- JMSVCTWVEWCHDZ-UHFFFAOYSA-N syringic acid Chemical compound COC1=CC(C(O)=O)=CC(OC)=C1O JMSVCTWVEWCHDZ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000191291 Abies alba Species 0.000 description 1
- 241000432824 Asparagus densiflorus Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- -1 alcohol ester Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000012237 paracetamol poisoning Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
The invention discloses purposes of the flowers poinsettia in beneficial liver effect product is prepared.With poinsettia as raw material, the beneficial liver product of all kinds of high-quality can be effectively converted to by extraction process and processing technology, including human and animal health-care products and natural drug product.
Description
Technical field
The present invention relates to the process technology of the flower plant " poinsettia " with the effect of beneficial liver and in health food and day
Purposes in right medicine, specifically, be it is fresh or dry poinsettia, deep processing and method for preparing extractive, poinsettia deeply plus
Purposes, one of chemical product, poinsettia extract, poinsettia active chemical, poinsettia in liver-protecting efficacy health products are prepared
The pinkish red application in the medicine for preparing hepatitis.
Background technology
Hepatopathy is the disease of serious harm people's health.China there are about 1.2 hundred million hepatitis B lifelong carriers at present, wherein
30000000 people can be transformed into chronic hepatitis, cirrhosis, liver cancer, and because of hepatopathy, the people of death there are about hundreds of thousands of them every year.In recent years,
The toxic hepatitis caused because of factors such as environmental pollution poisoning, occupational poisonings and by ebriosity and drug poisoning is also increasingly
Increase.China is used to treat the costly up to tens billion of yuans of hepatopathy every year, and national economy and social development is caused
Very big influence.Method due to still lacking specific treatment hepatitis at present, thus the new drug of exploitation treatment hepatopathy it is very urgent and
It is important.
Poinsettia (Euphorbia pulcherrima Willd.et Kl.) is a kind of to be viewed and admired colored by what people liked very much
Grass plant.English name：Common Poinsettia.Alias：Christmas tree, poinsettia, ivory are red, come tender etc. always.Poinsettia is big
The upright shrub of halberd section Euphorbia.《Chinese medicine Ci hai》In mention poinsettia its be bitter in taste, puckery, cold[1].Effect：Regulating menstruation, hemostasis, only
Cough, synthetism, subside a swelling.Cure mainly：Menorrhalgia, cough due to wind-cold evil, traumatic injury, traumatism and bleeding, fracture.Usage and dosage：It is for oral administration, decoct
Soup, 3~9 grams.External application：Fresh goods is smash deposited.Kong Lingyi and Min Zhi great are determined and are contained 5,7- dimethoxys in the cauline leaf of poinsettia
Cumarin, phthalic acid be double-(2- ethyls) alcohol ester, n-octadecane acid, syringic acid, forulic acid, Daucosterol and rutin
Deng[2].Animal experiment and the population epidemiology investigation of poinsettia think that poinsettia still compares safe plant[3,4]。
In addition to the application of the poinsettia mentioned in above-mentioned document is discussed, how to find its new medical value just turns into mesh
Preceding problem demanding prompt solution.Of the invention this is to be found that poinsettia treats the new application of hepatitis.
Bibliography in epimere word：
1. editorial board Chinese medicines Ci hai, China Medical Science Press publishes, the first volume, p14,1993
2. hole order is adopted；The research Chinese herbal medicines .1996 of the big poinsettia cauline leaf chemical compositions of Min Zhi；27(8):453-456
3.Winek CL；Butala J；Shanor SP；Fochtman FW.Toxicology of
poinsettia.Clin Toxicol；1978；13(1):27-45
4.Krenzelok EP；Jacobsen TD；Aronis JM.Poinsettia exposures have good
outcomes...just as we thought.Am J Emerg Med；VOL 14,ISS 7,1996；14(7):671-674
The content of the invention
It is an object of the invention to provide the new application of poinsettia, i.e., in the new opplication of the medicine for preparing hepatitis.
It is a further object of the present invention to provide a kind of medicine of hepatitis auxiliary treatment.
The purpose of the present invention also includes that offer prepares good poinsettia extract of convenient, therapeutic effect and preparation method thereof.
Inventor according to《2003 annual drug research technological guidance's principle --- Chinese medicine, natural goods fascicles》(state food
Drug Administration, 2003) and《New drug preclinical study guideline》(, national Bureau of Drugs Supervision in 1993) and《Health care
Food function assessment process》The hepatitis treatment medicine and health food evaluation method of (Ministry of Public Health 2003) etc., to poinsettia
Extract preparation, pharmaceutical dosage form preparation, animal pharmacology research are carried out.
The preparation method of poinsettia extract is：Poinsettia leaf or stem 1000g are taken, is crushed, washed 3~4 times, added water to cook
Three times, 15 minutes every time, collecting decoction, filtration, filtrate was condensed into the thick paste that relative density is 1.108~1.200, continued drying
Afterwards, fine powder processed, obtains final product.This product is the fine grained of brown.
Inventor's discovery, intraperitoneal injection and oral administration are carried out with poinsettia extract, there is obvious effect, serum liver
Dirty biochemical function index and pathological index all improve significantly.
When being treated with poinsettia extract, it can be with pulvis, granule, tablet, capsule, pill and liquid preparation
It is administered orally etc. form；Can also be with the form parenteral administration such as parenteral solution, suppository, percutaneous preparation, spray.Poinsettia is extracted
The effective agent of thing, be by with appropriate medicinal blend, such as excipient, adhesive, bleeding agent, lubricant mixing and match somebody with somebody
It is made.
Poinsettia extract doses change with the state of an illness of patient, method of administration, the age of patient and body weight.Orally giving
In the case of medicine, dosage is usually adult 1000~3000mg/ days, preferably 1500mg/ days.The dosage of health food also one
Sample.
It is an advantage of the invention that：Poinsettia can be as the edible natural plants flowers of beneficial liver.
Carbon tetrachloride is the toxic hepatitis model being widely used at present.Except the treatment of carbon tetrachloride poisoning has reality
Outside demand, also as the model of carbon tetrachloride hepatitis is more stable classical hepatitis model, it is health food and new drug
The evaluation method that will be used.
Paracetamol is analgesic-antipyretic the most frequently used in the world, but paracetamol causes poisoning in annual world wide
The case of property hepatitis has as many as thousands of.The anti-paracetamol poisoning of poinsettia all finds first at home and in the world, to control
Treat paracetamol hepatitis and provide a new treatment natural drug.
In addition, poinsettia preparation method is fairly simple, also comparing thoroughly for plant growth the characteristic study has certain scale
Planting base, so the source of medicinal material is secure.Market recognition is higher at home for medicinal plants, the acceptance in market
Height, good market prospect.
Specific embodiment
Examples provided below is not meant to limit the scope of the invention for the present invention is furture elucidated.
1. material
Poinsettia used by embodiment is bought from Pekinese flowers market.The cauline leaf of clip aerial part, cauline leaf is dried in the air together
It is dry, cauline leaf can also be separated, individually dry.Segment is cut into after drying standby.Fresh cauline leaf can also directly be used as medicine.
Other medicines, reagent and experimental animal, can easily city buys from the market.
2. preparation method example
The stem or leaf of poinsettia：The stem or leaf of poinsettia are taken respectively, or cauline leaf is added together, common 1000g, is cut into small
Section, is washed 3 times, and the 3000ml that adds water is decocted, totally three times, 15 minutes every time, collecting decoction, and filtration, filtrate is concentrated to dryness, or spraying
Dry, obtain brown ceramic powder, obtain final product.
Application example is enumerated：
(1) 1kg poinsettia extracts are taken to crush and cross 100 mesh sieves, adds appropriate amount of starch to mix, prepare granule, whole grain
After dispensed, every bag of 2g.
(2) poinsettia extract 1000g is taken, hydroxyethyl cellulose 10g, compressing tablet is made tablet, is placed on the device of air drying
It is standby in ware.
(3) poinsettia extract can on demand use normal saline parenteral solution.
(4) poinsettia extract can be formulated directly into oral liquid.
(5) poinsettia extract can coordinate with the medicine such as eryuelan extract, desert beans extract and be made compound mixture
For treating hepatitis.
3. test method (the treatment drug efficacy study of the anti-hepatitis of poinsettia extract)
Experimental animal is male and healthy mouse, and body weight is 22~26g.Enough running water and common feedings are provided during experiment
Material, animal housing keeps 22 DEG C, automatic ventilation.The packet of animal and treatment：Mouse is grouped at random by body weight.Toxic hepatitis is made
Any treatment, the 4th day hypodermic injection modeling compound are not given within 3 days before module.Poinsettia extract+modeling compound group difference
With various dose poinsettia extract gavage 4 days, once a day.30 minutes after 4th day gastric infusion, subcutaneous or intraperitoneal injection is made
Mold compound solution.After modeling compound is contaminated 24 hours, blood is taken, determine alanine transaminase (ALT) and asparagus fern ammonia in serum
Sour transferase (AST) and lactic dehydrogenase (LDH) activity.Statistical analysis technique：Experimental data is represented with mean ± standard deviation.
Experimental result is analyzed and processed using methods such as variance analysis, t inspections using EXCEL statistical softwares, p<0.05 thinks poor between group
It is different with conspicuousness.
Conclusion (of pressure testing)：Poinsettia has obvious benefit liver to act on.
4. result of the test：
(1) effect of the anti-paracetamol mouse toxic hepatitis of poinsettia extract can be found in table 1.
(2) effect of the anti-carbon tetrachloride mouse toxic hepatitis of poinsettia extract can be found in table 2.
The effect (serum liver function indexes) of the anti-paracetamol toxic hepatitis of the poinsettia extract of table 1
Note：Compare with paracetamol hepatitis group, * p ﹤ 0.05；* p ﹤ 0.01 (n=5)
The effect (serum liver function indexes) of the poinsettia stem of table 2 or the anti-carbon tetrachloride poisoning hepatitis of leaf
Note：Compare with carbon tetrachloride hepatitis group, * p ﹤ 0.05；* p ﹤ 0.01 (n=5).
Claims (7)
1. it is used to prepare the plant product having to human and animal's benefit liver effect, it is characterised in that contain poinsettia and its extraction
Thing.
2. a kind of poinsettia medicine materical crude slice, it is characterised in that poinsettia can be made crude drug medicine materical crude slice.
3. a kind of poinsettia extract, it is characterised in that adopt and prepare with the following method, take poinsettia, add water to cook three times,
15 minutes every time, collecting decoction, filtration after drying, was obtained fine powder.
4. poinsettia extract according to claim 3, it is characterised in that extract fine powder and appropriate medical dressing one
Rising can be made various formulations such as oral formulations, injection, granule, tablet, capsule, pill, powder.Can also and other
Medicine or other plant extracts compatibilities composition compound preparation.
5. a kind of medicine for hepatitis auxiliary treatment, it is characterised in that contain the poinsettia described in claim 2 and 3 or extraction
Thing.
6. a kind of health products for beneficial liver, it is characterised in that contain the poinsettia described in claim 2 and 3 or extract.
7. poinsettia or the poinsettia extract described in claim 2 and 3 are in the medicine and health products for preparing hepatitis
Application.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051786.3A CN106727872A (en) | 2017-01-20 | 2017-01-20 | The beneficial liver effect of poinsettia and application technology |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710051786.3A CN106727872A (en) | 2017-01-20 | 2017-01-20 | The beneficial liver effect of poinsettia and application technology |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106727872A true CN106727872A (en) | 2017-05-31 |
Family
ID=58941723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710051786.3A Withdrawn CN106727872A (en) | 2017-01-20 | 2017-01-20 | The beneficial liver effect of poinsettia and application technology |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727872A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050090A (en) * | 2017-06-26 | 2017-08-18 | 北京健旭康技术有限公司 | The effect of beneficial liver and its application of high mountain horseradish dish |
| CN107320505A (en) * | 2017-07-13 | 2017-11-07 | 北京健旭康技术有限公司 | The effect of beneficial liver and its application of durian |
| CN107684573A (en) * | 2017-09-27 | 2018-02-13 | 北京健旭康技术有限公司 | Purposes of the psoralea corylifolia in drug-breaking medicine and drug rehabilitation health food is prepared |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103960649A (en) * | 2014-05-15 | 2014-08-06 | 盐城工学院 | Caramel pigment with health-care function |
| CN104095905A (en) * | 2013-04-08 | 2014-10-15 | 北京健旭康技术有限公司 | Leguminosae plant with liver-tonifying effect and application thereof |
| CN106138648A (en) * | 2015-08-19 | 2016-11-23 | 北京健旭康技术有限公司 | The liver benefiting effect of head and application thereof |
-
2017
- 2017-01-20 CN CN201710051786.3A patent/CN106727872A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095905A (en) * | 2013-04-08 | 2014-10-15 | 北京健旭康技术有限公司 | Leguminosae plant with liver-tonifying effect and application thereof |
| CN103960649A (en) * | 2014-05-15 | 2014-08-06 | 盐城工学院 | Caramel pigment with health-care function |
| CN106138648A (en) * | 2015-08-19 | 2016-11-23 | 北京健旭康技术有限公司 | The liver benefiting effect of head and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邓拓: "《燕山夜话》", 30 November 2010, 北京十月文艺出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107050090A (en) * | 2017-06-26 | 2017-08-18 | 北京健旭康技术有限公司 | The effect of beneficial liver and its application of high mountain horseradish dish |
| CN107320505A (en) * | 2017-07-13 | 2017-11-07 | 北京健旭康技术有限公司 | The effect of beneficial liver and its application of durian |
| CN107684573A (en) * | 2017-09-27 | 2018-02-13 | 北京健旭康技术有限公司 | Purposes of the psoralea corylifolia in drug-breaking medicine and drug rehabilitation health food is prepared |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Alkandahri et al. | Antidiabetic activity of extract and fractions of Castanopsis costata leaves on alloxan-induced diabetic mice | |
| CN106727872A (en) | The beneficial liver effect of poinsettia and application technology | |
| CN103830301A (en) | Flos chrysanthemi with liver tonifying function and application thereof | |
| CN105998110A (en) | Condiment root with liver benefiting effect and application thereof | |
| CN101926852B (en) | Application of roots and leaves of common fig in preparing auxiliary therapy medicine and health food for hepatitis | |
| CN1861104B (en) | Inula flower extractive used to breat diabets mellitus and hyperlipidemia | |
| CN108497498A (en) | A kind of functional food of relieving alcoholism and protecting liver and preparation method thereof | |
| CN106692761A (en) | Corn with liver tonifying function and application of corn | |
| CN105230970A (en) | Feed additive for poultry and preparation method of feed additive | |
| CN1325094C (en) | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method | |
| CN107050090A (en) | The effect of beneficial liver and its application of high mountain horseradish dish | |
| CN106173240A (en) | A kind of liver protecting function and service plant extract feed additive and preparation technology | |
| CN104095905A (en) | Leguminosae plant with liver-tonifying effect and application thereof | |
| KR102165239B1 (en) | Hepatoprotective Composition Comprising Abeliophyllum Distichum Extract | |
| CN103655666B (en) | A kind of plant with beneficial liver effect and application thereof | |
| CN105998564A (en) | Allium plant with liver benefiting function and application thereof | |
| CN1284553C (en) | Application of five-finger fig in preparing adjuvant for treating hepatitis and health foods | |
| CN107496476A (en) | The beneficial liver effect of yunna cowparsnip and application technology | |
| CN105998353A (en) | Potato with liver benefiting effect and application thereof | |
| KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
| CN107496485A (en) | The beneficial liver effect of pilose gerbera herb and application technology | |
| CN106138648A (en) | The liver benefiting effect of head and application thereof | |
| CN105998152A (en) | Dioscorea opposita Thunb. with liver benefiting effect and application thereof | |
| CN106138647A (en) | The liver benefiting effect of Folium Allii tuberosi and application thereof | |
| CN107320505A (en) | The effect of beneficial liver and its application of durian |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170531 |
|
| WW01 | Invention patent application withdrawn after publication |